Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
200 participants
OBSERVATIONAL
2022-12-28
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
NCT05590221
Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma
NCT07198464
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT06876688
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
NCT02061761
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Relmacabtagene Autoleucel
Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
Relmacabtagene Autoleucel
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Relmacabtagene Autoleucel
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients already treated with commercially available Relmacabtagene Autoleucel
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Ming Ju Biotechnology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weili Zhao, PhD
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Huiqiang Huang, PhD
Role: PRINCIPAL_INVESTIGATOR
Sun Yat-sen University
Liang Huang, PhD
Role: PRINCIPAL_INVESTIGATOR
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Ping Li
Role: PRINCIPAL_INVESTIGATOR
Shanghai Tongji Hospital, Tongji University School of Medicine
Heng Mei
Role: PRINCIPAL_INVESTIGATOR
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hongmei Jing
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Wenbin Qian
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Depei Wu
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Soochow University
Ying Lu
Role: PRINCIPAL_INVESTIGATOR
Ningbo University People's Hospital
Huilai Zhang
Role: PRINCIPAL_INVESTIGATOR
Tianjin Cancer Hospital
Qingyuan Zhang
Role: PRINCIPAL_INVESTIGATOR
Harbin Medical University Tumor Hospital
Dehui Zou
Role: PRINCIPAL_INVESTIGATOR
Hematology Hospital, Chinese Academy of Medical Sciences
Yao Liu
Role: PRINCIPAL_INVESTIGATOR
Chongqing University Cancer Hospital
Jianqiu Wu
Role: PRINCIPAL_INVESTIGATOR
Jiangsu Provincial Tumor Hospital
Yajun Li
Role: PRINCIPAL_INVESTIGATOR
Hunan Cancer Hospital
Ru Feng
Role: PRINCIPAL_INVESTIGATOR
Southern Medical University, China
Yuhua Li
Role: PRINCIPAL_INVESTIGATOR
Nanfang Hospital, Southern Medical University
Zhifeng Li
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Xiamen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Weili Zhao, PhD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Weili Zhao, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JWCAR029-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.